Aslan reports Phase II varlitinib results ahead of IPO

Aslan Pharmaceuticals Ltd. (Singapore) said lead candidate varlitinib (ASLAN001) led to greater tumor shrinkage compared to Tykerb lapatinib in a Phase II study to treat advanced, HER2-positive breast cancer. Varlitinib is an oral small molecule inhibitor of EGFR and HER2.

The results come as Aslan prepares to conduct an IPO on Taiwan's Taipei Exchange. CEO Carl Firth told BioCentury the company expects to begin trading next quarter, pending market conditions...